Monocyte-to-HDL-C ratio (MHR) was found to be correlated with gout risk and renal dysfunction severity in a new cross-sectional study.1 “High monocyte counts and low HDL-C levels positively correlate with …
Tag:
treatments
-
-
Emerging Anemia Treatments for Dialysis Patients: A Closer Look at HIF-PHIs March 26, 2025 For over 500,000 Americans on dialysis because of chronic kidney disease (CKD), anemia remains a significant …
-
Dr. Anya Sharma on Groundbreaking Medical Innovations: A Sneak Peek into Future Healthcare In a compelling interview with Dr. Anya Sharma, Chief Medical Officer at Global Health Innovations, we delve …
-
Growing Concerns: GLP-1 RAs and the Link to Thyroid Cancer The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in treating type 2 diabetes (T2D) has exploded in recent years. …
-
New Research Links GLP-1 RA Use to Reduced Stroke Risk in Type 2 Diabetes Patients Rushad Patell, MDCredit: BIDMC A recent study published at the 66th American Society of Hematology …
-
Daylight Saving Time: Enjoy the Extra Hour, But Watch for Seasonal Affective Disorder (SAD) Getting that extra hour of sleep this weekend sounds fantastic, but unfortunately, the shift in time …
-
Henning Bliddal, MD, MSci Credit: The Parker Institute Semaglutide Shows Promise in Reducing Knee Osteoarthritis Pain in Obese Individuals In a groundbreaking study, semaglutide, a medication primarily known for its …
-
New Hope for IgA Nephropathy: Promising Treatment Advancements The landscape of IgA nephropathy (IgAN) management is experiencing a remarkable transformation. Driven by decades of research unraveling the disease’s intricate pathophysiology, …
-
Lean Liver Disease: A Hidden Threat Affecting Millions of Americans New research is shining a light on a concerning trend: lean metabolic dysfunction-associated steatotic liver disease (MASLD) is affecting a …
-
Health
Semaglutide for Nondiabetic Kidney Disease, with Hiddo Heerspink, PhD, PharmD, at Kidney Week 2024
Semaglutide Shows Promise for Non-Diabetic Chronic Kidney Disease in Landmark SMART Trial Exciting news emerged from Kidney Week 2024 as the landmark SMART trial unveiled promising results for semaglutide (Ozempic/Wegovy) …